ANN ARBOR, MI--(Marketwire - February 29, 2008) - Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it has completed a Type A meeting with the FDA regarding its previously submitted New Drug Application (NDA) for oral tetrathiomolybdate for the treatment of initially presenting neurologic Wilson’s disease.
